Literature DB >> 7476733

[Recommendations of the German Society of Clinical Pharmacology and Therapy for implementing and evaluating pharmaco-economic studies].

J G Brecht1, A Jenke, M E Köhler, S Harder, P Thürmann, N Rietbrock.   

Abstract

Mesh：

Year:  1995        PMID： 7476733

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN： 0723-5003


× No keyword cloud information.
  7 in total

1.  Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.

Authors:  Peter K Schädlich; Henning Zeidler; Angela Zink; Erika Gromnica-Ihle; Matthias Schneider; Christoph Straub; Josef G Brecht; Eduard Huppertz
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  [Structure and activities of drug committees in Germany. Results of a survey of 143 hospitals. Pharmaco-economic Study Group and Rational Drug Therapy of the German Society of Clinical Pharmacology and Therapy].

Authors:  S Harder; P Thürmann; A Steioff
Journal:  Med Klin (Munich)       Date:  1998-02-15

3.  Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany.

Authors:  P K Schädlich; J G Brecht
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

4.  Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.

Authors:  Peter K Schädlich; Michael Kentsch; Manfred Weber; Wolfgang Kämmerer; Josef Georg Brecht; Vijay Nadipelli; Eduard Huppertz
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study.

Authors:  P K Schädlich; J G Brecht
Journal:  Pharmacoeconomics       Date:  1998-06       Impact factor: 4.981

6.  Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.

Authors:  Peter K Schädlich; Henning Zeidler; Angela Zink; Erika Gromnica-Ihle; Matthias Schneider; Christoph Straub; Josef G Brecht; Eduard Huppertz
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.

Authors:  Peter K Schädlich; Josef Georg Brecht; Badrudin Rangoonwala; Eduard Huppertz
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.